Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-05-19 22:00 |
Nicox : Mise à disposition d'un amendement au Document d’enregistrement univers…
|
French | 317.9 KB | ||
| 2022-05-16 07:30 |
Nicox Announces a New Governance Structure
|
English | 344.3 KB | ||
| 2022-05-16 07:30 |
Nicox Annonce une Nouvelle Structure de Gouvernance
|
French | 435.4 KB | ||
| 2022-05-04 17:45 |
Number of voting rights as of May 4, 2022
|
English | 189.8 KB | ||
| 2022-05-04 17:45 |
Nombre de droits de vote au 4 mai 2022
|
French | 188.9 KB | ||
| 2022-05-04 07:30 |
Nicox : Assemblée Générale Ordinaire 2022
|
French | 321.7 KB | ||
| 2022-05-04 07:30 |
Nicox: 2022 Ordinary Shareholder Meeting
|
English | 249.2 KB | ||
| 2022-05-02 17:45 |
Nombre de droits de vote au 30 avril 2022
|
French | 188.9 KB | ||
| 2022-05-02 17:45 |
Number of voting rights as of April 30, 2022
|
English | 189.8 KB | ||
| 2022-05-02 07:30 |
Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251 and ne…
|
English | 322.3 KB | ||
| 2022-05-02 07:30 |
Nicox: Présentation au congrès de l’ARVO 2022 de résultats de l’étude de phase …
|
French | 323.3 KB | ||
| 2022-04-29 19:00 |
Nicox : Document d’enregistrement universel 2021
|
French | 319.3 KB | ||
| 2022-04-29 09:12 |
DOCUMENT ENREGISTREMENT UNIVERSEL
|
French | 9.8 MB | ||
| 2022-04-29 09:12 |
DOCUMENT ENREGISTREMENT UNIVERSEL
|
French | 9.8 MB | ||
| 2022-04-28 07:30 |
Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlight…
|
English | 512.1 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
